Egalet Corp. (NASDAQ:EGLT) shares dropped 1% during mid-day trading on Thursday . The stock traded as low as $7.95 and last traded at $8.02, with a volume of 150,969 shares traded. The stock had previously closed at $8.10.

EGLT has been the subject of several research reports. Zacks Investment Research lowered Egalet Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, August 9th. Cantor Fitzgerald reissued a “buy” rating on shares of Egalet Corp. in a research report on Tuesday, June 28th.

The company’s market cap is $195.61 million. The firm has a 50 day moving average of $6.93 and a 200-day moving average of $6.58.

Egalet Corp. (NASDAQ:EGLT) last released its quarterly earnings results on Thursday, August 4th. The specialty pharmaceutical company reported ($0.97) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.82) by $0.15. During the same period in the prior year, the company posted ($1.03) EPS. The company earned $3.45 million during the quarter, compared to the consensus estimate of $3.83 million. The company’s quarterly revenue was up 259.4% compared to the same quarter last year. Analysts forecast that Egalet Corp. will post ($3.47) earnings per share for the current fiscal year.

In related news, CFO Stan Musial sold 13,480 shares of Egalet Corp. stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $5.06, for a total value of $68,208.80. Following the completion of the transaction, the chief financial officer now owns 84,940 shares in the company, valued at $429,796.40. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Robert S. Radie sold 15,000 shares of Egalet Corp. stock in a transaction dated Wednesday, July 6th. The stock was sold at an average price of $5.01, for a total value of $75,150.00. Following the completion of the transaction, the chief executive officer now owns 259,900 shares of the company’s stock, valued at approximately $1,302,099. The disclosure for this sale can be found here.

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.